Head to Head Review: Ironwood Pharmaceuticals (NASDAQ:IRWD) vs. Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Volatility & Risk

Dyne Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Insider & Institutional Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 12.7% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Dyne Therapeutics and Ironwood Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$317.42 million	($3.86)	-4.72
Ironwood Pharmaceuticals	$308.52 million	1.08	$880,000.00	($0.05)	-41.00

Ironwood Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Dyne Therapeutics and Ironwood Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	3	10	4	2.94
Ironwood Pharmaceuticals	1	6	1	0	2.00

Dyne Therapeutics currently has a consensus price target of $34.53, indicating a potential upside of 89.74%. Ironwood Pharmaceuticals has a consensus price target of $4.94, indicating a potential upside of 140.98%. Given Ironwood Pharmaceuticals’ higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Dyne Therapeutics.

Profitability

This table compares Dyne Therapeutics and Ironwood Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.12%	-56.75%
Ironwood Pharmaceuticals	-2.25%	-2.46%	2.19%

Summary

Dyne Therapeutics beats Ironwood Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.